

TABLE OF CONTENTS

BY DOMAIN

ADVERSE EVENT SUMMARY	14
ADVERSE EVENTS	14
ADVERSE EVENT	15
COMPLETE PHYSICAL EXAMINATION	18
BASELINE	18
BASELINE/DAY 1 RETREATMENT	18
EARLY TERMINATION (INITIAL TREATMENT)	18
EARLY TERMINATION (RETREATMENT)	18
POST-RETREATMENT FOLLOW-UP WEEK 4	18
POST-RETREATMENT FOLLOW-UP WEEK 24	18
POST-TREATMENT FOLLOW-UP WEEK 4	18
POST-TREATMENT FOLLOW-UP WEEK 24	18
SCREENING	18
SCREENING RETREATMENT	18
UNSCHEDULED	18
WEEK 6	18
WEEK 12	18
WEEK 24	18
WEEK 24 RETREATMENT	18
WEEK 48 RETREATMENT	18
CONCOMITANT MEDICATION SUMMARY	19
CONCOMITANT MEDICATION	19
CONCOMITANT MEDICATION	20
CONCOMITANT MEDICATION	20
DEATH REPORT	21
DEATH	21
DEMOGRAPHICS	22
SCREENING	22
DOSE ADMINISTRATION (DAY 1) - ARM 1	23
BASELINE	23
DOSE ADMINISTRATION (DAY 1) - ARM 2	24
BASELINE	24
ECG	25

BASLINE	25
BASLINE/DAY 1 RETREATMENT	25
EARLY TERMINATION (INITIAL TREATMENT)	25
EARLY TERMINATION (RETREATMENT)	25
SCREENING	25
SCREENING RETREATMENT	25
UNSCHEDULED	25
WEEK 6	25
WEEK 12	25
WEEK 24	25
WEEK 24 RETREATMENT	25
WEEK 48 RETREATMENT	25
GENERAL COMMENTS	26
GENERAL COMMENTS	26
INCLUSION/EXCLUSION CRITERIA (RETREATMENT)	31
SCREENING RETREATMENT	31
INCLUSION/EXCLUSION CRITERIA	32
SCREENING	32
INVESTIGATOR'S SIGNATURE	36
LIVER FIBROSIS ASSESSMENT	37
SCREENING	37
MEDICAL HISTORY	39
SCREENING	39
PREGNANCY REPORT	40
RANDOMIZATION	41
BASLINE	41
REGISTRY SUBSTUDY	42
RETREATMENT SUBSTUDY STATUS	43
RETREATMENT SUBSTUDY	43
STOP TREATMENT - RETREATMENT SUBSTUDY	44
WEEK 24 RETREATMENT	44
STOP TREATMENT	45
WEEK 2	45
WEEK 4	45
WEEK 6	45
STUDY COMPLETION	46
STUDY COMPLETION	46
STUDY DRUG ACCOUNTABILITY - GS-5885 RETREATMENT	47

STUDY DRUG ACCOUNTABILITY	47
STUDY DRUG ACCOUNTABILITY - GS-5885	48
STUDY DRUG ACCOUNTABILITY	48
STUDY DRUG ACCOUNTABILITY - GS-9451 RETREATMENT	49
STUDY DRUG ACCOUNTABILITY	49
STUDY DRUG ACCOUNTABILITY - GS-9451	50
STUDY DRUG ACCOUNTABILITY	50
STUDY DRUG ACCOUNTABILITY - PEG RETREATMENT	51
STUDY DRUG ACCOUNTABILITY	51
STUDY DRUG ACCOUNTABILITY - PEG	53
STUDY DRUG ACCOUNTABILITY	53
STUDY DRUG ACCOUNTABILITY - RBV RETREATMENT	54
STUDY DRUG ACCOUNTABILITY	54
STUDY DRUG ACCOUNTABILITY - RBV	56
STUDY DRUG ACCOUNTABILITY	56
STUDY DRUG ADMINISTRATION - INITIAL TREATMENT	57
STUDY DRUG ADMINISTRATION	57
STUDY DRUG ADMINISTRATION - RETREATMENT	58
STUDY DRUG ADMINISTRATION	58
STUDY DRUG COMPLETION (INITIAL TREATMENT)	59
STUDY DRUG COMPLETION (INITIAL TREATMENT)	59
STUDY DRUG COMPLETION (RETREATMENT)	60
STUDY DRUG COMPLETION (RETREATMENT)	60
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 4	61
POST-RETREATMENT FOLLOW-UP WEEK 8	61
POST-RETREATMENT FOLLOW-UP WEEK 12	61
POST-RETREATMENT FOLLOW-UP WEEK 16	61
POST-RETREATMENT FOLLOW-UP WEEK 20	61
POST-RETREATMENT FOLLOW-UP WEEK 24	61
POST-TREATMENT FOLLOW-UP WEEK 4	61
POST-TREATMENT FOLLOW-UP WEEK 8	61
POST-TREATMENT FOLLOW-UP WEEK 12	61
POST-TREATMENT FOLLOW-UP WEEK 16	61
POST-TREATMENT FOLLOW-UP WEEK 20	61
POST-TREATMENT FOLLOW-UP WEEK 24	61
SUBJECT NUMBER	62
URINE PREGNANCY TEST (BASELINE)	63

BASLINE	63
URINE PREGNANCY TEST	64
BASLINE/DAY 1 RETREATMENT	64
EARLY TERMINATION (INITIAL TREATMENT)	64
EARLY TERMINATION (RETREATMENT)	64
POST-RETREATMENT FOLLOW-UP MONTH 7	64
POST-RETREATMENT FOLLOW-UP WEEK 4	64
POST-RETREATMENT FOLLOW-UP WEEK 8	64
POST-RETREATMENT FOLLOW-UP WEEK 12	64
POST-RETREATMENT FOLLOW-UP WEEK 16	64
POST-RETREATMENT FOLLOW-UP WEEK 20	64
POST-RETREATMENT FOLLOW-UP WEEK 24	64
POST-RETREATMENT FOLLOW-UP WEEK 28	64
POST-TREATMENT FOLLOW-UP MONTH 7	64
POST-TREATMENT FOLLOW-UP WEEK 4	64
POST-TREATMENT FOLLOW-UP WEEK 8	64
POST-TREATMENT FOLLOW-UP WEEK 12	64
POST-TREATMENT FOLLOW-UP WEEK 16	64
POST-TREATMENT FOLLOW-UP WEEK 20	64
POST-TREATMENT FOLLOW-UP WEEK 24	64
POST-TREATMENT FOLLOW-UP WEEK 28	64
SCREENING RETREATMENT	64
UNSCHEDULED	64
WEEK 4	64
WEEK 4 RETREATMENT	64
WEEK 6	64
WEEK 8	64
WEEK 8 RETREATMENT	64
WEEK 10	64
WEEK 12	64
WEEK 12 RETREATMENT	64
WEEK 16	64
WEEK 16 RETREATMENT	64
WEEK 20	64
WEEK 20 RETREATMENT	64
WEEK 24	64
WEEK 24 RETREATMENT	64
WEEK 28 RETREATMENT	64

WEEK 32 RETREATMENT	64
WEEK 36 RETREATMENT	64
WEEK 40 RETREATMENT	64
WEEK 44 RETREATMENT	64
WEEK 48 RETREATMENT	64
VISIT DATE	65
BASELINE	65
BASELINE/DAY 1 RETREATMENT	65
EARLY TERMINATION (INITIAL TREATMENT)	65
EARLY TERMINATION (RETREATMENT)	65
POST-RETREATMENT FOLLOW-UP WEEK 4	65
POST-RETREATMENT FOLLOW-UP WEEK 12	65
POST-RETREATMENT FOLLOW-UP WEEK 24	65
POST-TREATMENT FOLLOW-UP WEEK 4	65
POST-TREATMENT FOLLOW-UP WEEK 12	65
POST-TREATMENT FOLLOW-UP WEEK 24	65
SCREENING	65
SCREENING RETREATMENT	65
UNSCHEDULED	65
WEEK 1	65
WEEK 1 RETREATMENT	65
WEEK 2	65
WEEK 2 RETREATMENT	65
WEEK 4	65
WEEK 4 RETREATMENT	65
WEEK 6	65
WEEK 8	65
WEEK 8 RETREATMENT	65
WEEK 10	65
WEEK 12	65
WEEK 12 RETREATMENT	65
WEEK 16	65
WEEK 16 RETREATMENT	65
WEEK 20	65
WEEK 20 RETREATMENT	65
WEEK 24	65
WEEK 24 RETREATMENT	65
WEEK 28 RETREATMENT	65

WEEK 32 RETREATMENT	65
WEEK 36 RETREATMENT	65
WEEK 40 RETREATMENT	65
WEEK 44 RETREATMENT	65
WEEK 48 RETREATMENT	65
VITAL SIGNS	66
BASELINE	66
BASELINE/DAY 1 RETREATMENT	66
EARLY TERMINATION (INITIAL TREATMENT)	66
EARLY TERMINATION (RETREATMENT)	66
POST-RETREATMENT FOLLOW-UP WEEK 4	66
POST-RETREATMENT FOLLOW-UP WEEK 12	66
POST-RETREATMENT FOLLOW-UP WEEK 24	66
POST-TREATMENT FOLLOW-UP WEEK 4	66
POST-TREATMENT FOLLOW-UP WEEK 12	66
POST-TREATMENT FOLLOW-UP WEEK 24	66
SCREENING	66
SCREENING RETREATMENT	66
UNSCHEDULED	66
WEEK 1	66
WEEK 1 RETREATMENT	66
WEEK 2	66
WEEK 2 RETREATMENT	66
WEEK 4	66
WEEK 4 RETREATMENT	66
WEEK 6	66
WEEK 8	66
WEEK 8 RETREATMENT	66
WEEK 10	66
WEEK 12	66
WEEK 12 RETREATMENT	66
WEEK 16	66
WEEK 16 RETREATMENT	66
WEEK 20	66
WEEK 20 RETREATMENT	66
WEEK 24	66
WEEK 24 RETREATMENT	66
WEEK 28 RETREATMENT	66

WEEK 32 RETREATMENT	66
WEEK 36 RETREATMENT	66
WEEK 40 RETREATMENT	66
WEEK 44 RETREATMENT	66
WEEK 48 RETREATMENT	66

BY VISIT

SCREENING	65
VISIT DATE	65
INCLUSION/EXCLUSION CRITERIA	32
DEMOGRAPHICS	22
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
MEDICAL HISTORY	39
LIVER FIBROSIS ASSESSMENT	37
ECG	25
BASELINE	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST (BASELINE)	63
RANDOMIZATION	41
DOSE ADMINISTRATION (DAY 1) - ARM 1	23
DOSE ADMINISTRATION (DAY 1) - ARM 2	24
WEEK 1	65
VISIT DATE	65
VITAL SIGNS	66
WEEK 2	65
VISIT DATE	65
VITAL SIGNS	66
STOP TREATMENT	45
WEEK 4	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
STOP TREATMENT	45
WEEK 6	65
VISIT DATE	65

VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
STOP TREATMENT	45
WEEK 8	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 10	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 12	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
WEEK 16	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 20	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 24	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
EARLY TERMINATION (INITIAL TREATMENT)	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25

URINE PREGNANCY TEST	64
STUDY DRUG COMPLETION (INITIAL TREATMENT)	59
STUDY DRUG COMPLETION (INITIAL TREATMENT)	59
POST-TREATMENT FOLLOW-UP WEEK 4	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 8	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 12	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 16	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 20	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 24	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-TREATMENT FOLLOW-UP WEEK 28	64
URINE PREGNANCY TEST	64
POST-TREATMENT FOLLOW-UP MONTH 7	64
URINE PREGNANCY TEST	64
RETREATMENT SUBSTUDY	43
RETREATMENT SUBSTUDY STATUS	43
SCREENING RETREATMENT	65
VISIT DATE	65
INCLUSION/EXCLUSION CRITERIA (RETREATMENT)	31

VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
BASELINE/DAY 1 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
WEEK 1 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
WEEK 2 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
WEEK 4 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 8 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 12 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 16 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 20 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 24 RETREATMENT	65
VISIT DATE	65

VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
STOP TREATMENT - RETREATMENT SUBSTUDY	44
WEEK 28 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 32 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 36 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 40 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 44 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
WEEK 48 RETREATMENT	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
EARLY TERMINATION (RETREATMENT)	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
STUDY DRUG COMPLETION (RETREATMENT)	60

STUDY DRUG COMPLETION (RETREATMENT)	60
POST-RETREATMENT FOLLOW-UP WEEK 4	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 8	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 12	65
VISIT DATE	65
VITAL SIGNS	66
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 16	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 20	64
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 24	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
URINE PREGNANCY TEST	64
SUBJECT FOLLOW-UP STATUS	61
POST-RETREATMENT FOLLOW-UP WEEK 28	64
URINE PREGNANCY TEST	64
POST-RETREATMENT FOLLOW-UP MONTH 7	64
URINE PREGNANCY TEST	64
ADVERSE EVENTS	14
ADVERSE EVENT SUMMARY	14
CONCOMITANT MEDICATION	19
CONCOMITANT MEDICATION SUMMARY	19
CONCOMITANT MEDICATION	20
STUDY DRUG ADMINISTRATION	57
STUDY DRUG ADMINISTRATION - INITIAL TREATMENT	57

STUDY DRUG ADMINISTRATION - RETREATMENT	58
STUDY DRUG ACCOUNTABILITY	48
STUDY DRUG ACCOUNTABILITY - GS-5885	48
STUDY DRUG ACCOUNTABILITY - GS-9451	50
STUDY DRUG ACCOUNTABILITY - RBV	56
STUDY DRUG ACCOUNTABILITY - PEG	53
STUDY DRUG ACCOUNTABILITY - GS-5885 RETREATMENT	47
STUDY DRUG ACCOUNTABILITY - GS-9451 RETREATMENT	49
STUDY DRUG ACCOUNTABILITY - RBV RETREATMENT	54
STUDY DRUG ACCOUNTABILITY - PEG RETREATMENT	51
DEATH	21
DEATH REPORT	21
GENERAL COMMENTS	26
GENERAL COMMENTS	26
UNSCHEDULED	65
VISIT DATE	65
VITAL SIGNS	66
COMPLETE PHYSICAL EXAMINATION	18
ECG	25
URINE PREGNANCY TEST	64
STUDY COMPLETION	46
STUDY COMPLETION	46
PREGNANCY REPORT	40
INVESTIGATOR'S SIGNATURE	36
SUBJECT NUMBER	62

Project Name: GS-US-248-0121

Form: Adverse Event Summary [AES]

Generated On: 07-31-2013 09:44:51

Did the subject experience any Adverse Events during the course of the study?

☐ Yes

☐ No

Project Name: GS-US-248-0121

Form: Adverse Event [AE]

Generated On: 07-31-2013 09:44:51

Adverse Event:

(List diagnosis or each symptom separately)

AE serious:

(If the Adverse Event is Serious, please click the [?] help text to open the SAE Report Form in another window. Print and fill in all the information for the first three pages on the SAE form and fax to the appropriate CRO contact)

☐ Yes

☐ No

Start Date: (DD-MMM-YYYY)

End Date: (DD-MMM-YYYY)

Please check if Ongoing:

☐

Related to any of the Study Drugs:

☐ Yes

(All study drugs are to be considered in assessment of relationship to study drugs: GS-5885, GS-9451, RBV and PEG)

☐ No

Related to Study Procedures:

☐ Yes

☐ No

Study Drug Action Taken - GS-5885:

- ☐ No Change
- ☐ Interrupted
- ☐ Discontinued
- ☐ Not Applicable

Study Drug Action Taken - GS-9451:

- ☐ No Change
- ☐ Interrupted
- ☐ Discontinued
- ☐ Not Applicable

Study Drug Action Taken - RBV:

- ☐ No change
- ☐ Interrupted
- ☐ Discontinued
- ☐ Dose Reduced
- ☐ Not Applicable

Project Name: GS-US-248-0121

Form: Adverse Event [AE]

Generated On: 07-31-2013 09:44:51

Study Drug Action Taken - PEG:

- ☐ No change
- ☐ Interrupted
- ☐ Discontinued
- ☐ Dose Reduced
- ☐ Not Applicable

Severity:

- ☐ Mild
- ☐ Moderate
- ☐ Severe
- ☐ Life-Threatening

Other Action Taken: (Check all that apply)
None:

☐

Medication Required:

☐

Hospitalized/Prolonged Hospitalization:

☐

Other Treatment Required:

☐

Hidden field for AE_AESER_ALERT

Note: To add additional adverse events, please complete an additional form, by clicking on 'Add a new log line'.

If Adverse Event is Serious, please refer to the regulatory binder for an SAE Report form. Complete an SAE Report and E-mail or fax the SAE Report within 24 hours of the Reporter's knowledge of the event. Contact information for faxing and e-mailing this form is found in the study protocol in section 8.5.

Project Name: GS-US-248-0121
Form: Adverse Event [AE]
Generated On: 07-31-2013 09:44:51

Contact information for faxing and e-mailing these forms:

Australia/New Zealand (PRA Pharmacovigilance)

Fax +1 (888) 772-6919

Phone +1 (800) 772-2215

Email: CHO_safety@praintl.com

USA/Canada (DCRI Pharmacovigilance)

Fax +1 (866) 668-7139

Phone +1 (866) 668-7799

Email: safetysurveillance@mc.duke.edu

A Serious Adverse Event is any adverse experience that results in any of the following outcomes:

- (1) Death,**
- (2) Is life-threatening (at immediate risk of death at time of the event),**
- (3) Requires subject hospitalization or prolonged hospitalization,**
- (4) Persistent or significant disability/incapacity,**
- (5) Congenital abnormality/birth defect or**
- (6) Any other important Medical Event based on clinician's judgment or may require medical or surgical intervention to prevent one of the other serious criteria.**

Refer to protocol for protocol-specific SAE definitions.

Project Name: GS-US-248-0121
Form: Complete Physical Examination [PE]
Generated On: 07-31-2013 09:44:51

Select a response for each body system. If a body system is not examined, select "Not Done."

Body System

- ☐ Head, Neck & Thyroid
- ☐ Eyes, Ears, Nose, Throat, Mouth & Tongue
- ☐ Chest (Excluding breasts)
- ☐ Respiratory
- ☐ Cardiovascular
- ☐ Lymph Nodes
- ☐ Abdomen
- ☐ Skin, Nails & Hair
- ☐ Musculoskeletal
- ☐ Neurological
- ☐ Retinal Exam
- ☐ Other

If Body System is Other, please specify:

Result:

- ☐ Abnormal
- ☐ Normal
- ☐ Not Done

If "Abnormal", please describe abnormal physical findings:

If additional Body Systems are needed then click on 'Add New Log Line' at the bottom of the form. Enter the Result, and Abnormality if applicable, then click on 'Save'. Specify the Body system under If Body System is Other, please specify then click on 'Save' again.

Project Name: GS-US-248-0121

Form: Concomitant Medication Summary [CMS]

Generated On: 07-31-2013 09:44:51

Did the subject take any Medications from time of informed consent signing through study completion?

☐ Yes

☐ No

Project Name: GS-US-248-0121

Form: Concomitant Medication [CM]

Generated On: 07-31-2013 09:44:51

Drug Name:

Indication: (Use Medical Terminology)

Route:

- ☐ Inhalation
- ☐ Intradermal
- ☐ Intralesional
- ☐ Intramuscular
- ☐ Intranasal
- ☐ Intravenous
- ☐ Intraocular
- ☐ Intraperitoneal
- ☐ Oral
- ☐ Rectal
- ☐ Subcutaneous
- ☐ Sublingual
- ☐ Topical
- ☐ Vaginal
- ☐ Other

If "Other", please specify:

Start Date: (DD-MMM-YYYY)

Stop Date: (DD-MMM-YYYY)

Please check if Ongoing:

☐

Note: To add additional concomitant medications, please complete an additional form, by clicking on 'Add a new log line'.

Project Name: GS-US-248-0121
Form: Death Report [DEATH]
Generated On: 07-31-2013 09:44:51

In addition to this eCRF, please refer to the regulatory binder for an SAE Report form. Complete an SAE Report and E-mail or fax the SAE Report within 24 hours of the Reporter's knowledge of the event. Please also send a copy of the discharge/death summary and autopsy report, if available.

Contact information for faxing and e-mailing these forms is found in the study protocol in section 8.5.(Click the [?] help text to open the SAE Report Form in another window. Please fill in all appropriate information on the first three pages before faxing the forms to the appropriate CRO contact.)

Contact information for faxing and e-mailing these forms:

Australia/New Zealand (PRA Pharmacovigilance)

Fax +1 (888) 772-6919

Phone +1 (800) 772-2215

Email: CHO_safety@praintl.com

USA/Canada (DCRI Pharmacovigilance)

Fax +1 (866) 668-7139

Phone +1 (866) 668-7799

Email: safetysurveillance@mc.duke.edu

Please update the Adverse Event eCRF, as needed.

Date of Death: (DD-MMM-YYYY)

Immediate Cause of Death:

Project Name: GS-US-248-0121

Form: Demographics [DM]

Generated On: 07-31-2013 09:44:51

Date of Birth: (DD-MMM-YYYY)

Age:

Sex:

☐

Male

☐

Female

Ethnicity:

☐

Hispanic or Latino

☐

Not Hispanic or Latino

Race:

☐

American Indian or Alaska Native

☐

Asian

☐

Black or African Heritage

☐

Native Hawaiian or Pacific Islander

☐

White

☐

Other

If "Other", please specify:

Year of Birth (yyyy)

Project Name: GS-US-248-0121

Form: Dose Administration (Day 1) - Arm 1 [PKEX]

Generated On: 07-31-2013 09:44:51

Name of Actual Treatment:

☐ GS-5885

☐ GS-9451

☐ RBV

☐ PEG

Date of First Dose: (DD-MMM-YYYY)

Time of First Dose: (00:00-23:59)

Dose:

Dose Units:

☐ mg

☐ ug

☐ tablets

☐ capsules

Dose Taken With Food:

☐ Yes

☐ No

PEG Date of First Dose: (DD-MMM-YYYY)

PEG Time of First Dose: (00:00-23:59)

PEG Dose:

PEG Dose Units:

☐ mg

☒ ug

☐ tablets

☐ capsules

Project Name: GS-US-248-0121

Form: Dose Administration (Day 1) - Arm 2 [PKEX2]

Generated On: 07-31-2013 09:44:51

Name of Actual Treatment:

☐ GS-5885

☐ GS-9451

☐ RBV

☐ PEG

Date of First Dose: (DD-MMM-YYYY)

Time of First Dose: (00:00-23:59)

Dose:

Dose Units:

☐ mg

☐ ug

☐ tablets

☐ capsules

Dose Taken With Food:

☐ Yes

☐ No

PEG Date of First Dose: (DD-MMM-YYYY)

PEG Time of First Dose: (00:00-23:59)

PEG Dose:

PEG Dose Units:

☐ mg

☒ ug

☐ tablets

☐ capsules

Project Name: GS-US-248-0121

Form: ECG [EG]

Generated On: 07-31-2013 09:44:51

Was an ECG performed?

☐ Yes

☐ No

If No, please comment why ECG was not done:

Date of ECG:

Time of ECG (00:00-23:59):

Overall Assessment of ECG:

☐ Normal

☐ Abnormal

If Abnormal, please describe the abnormality:

Significance of Abnormality:

☐ Not Clinically Significant

☐ Clinically Significant

Project Name: GS-US-248-0121
Form: General Comments [CO]
Generated On: 07-31-2013 09:44:51

Visit:

- ☐ Screening
 - ☐ Initial Treatment Visits
 - ☐ Baseline
 - ☐ Week 1
 - ☐ Week 2
 - ☐ Week 4
 - ☐ Week 6
 - ☐ Week 8
 - ☐ Week 10
 - ☐ Week 12
 - ☐ Week 16
 - ☐ Week 20
 - ☐ Week 24
 - ☐ Early Termination (Initial Treatment)
 - ☐ Study Drug Completion (Initial Treatment)
 - ☐ Dose Administration
 - ☐ Post-Treatment Follow-Up Week 4
 - ☐ Post-Treatment Follow-Up Week 8
 - ☐ Post-Treatment Follow-Up Week 12
 - ☐ Post-Treatment Follow-Up Week 16
 - ☐ Post-Treatment Follow-Up Week 20
 - ☐ Post-Treatment Follow-Up Week 24
 - ☐ Post-Treatment Follow-Up Week 28
 - ☐ Post-Treatment Follow-Up Month 7
 - ☐ Retreatment Substudy
 - ☐ Baseline/Day 1 Retreatment
 - ☐ Week 1 Retreatment
 - ☐ Week 2 Retreatment
 - ☐ Week 4 Retreatment
-

- ☐ Week 6 Retreatment
 - ☐ Week 8 Retreatment
 - ☐ Week 10 Retreatment
 - ☐ Week 12 Retreatment
 - ☐ Week 16 Retreatment
 - ☐ Week 20 Retreatment
 - ☐ Week 24 Retreatment
 - ☐ Week 28 Retreatment
 - ☐ Week 32 Retreatment
 - ☐ Week 36 Retreatment
 - ☐ Week 40 Retreatment
 - ☐ Week 44 Retreatment
 - ☐ Week 48 Retreatment
 - ☐ Early Termination (Retreatment)
 - ☐ Post-Retreatment Follow-Up
Week 4
 - ☐ Post-Retreatment Follow-Up
Week 8
 - ☐ Post-Retreatment Follow-Up
Week 12
 - ☐ Post-Retreatment Follow-Up
Week 16
 - ☐ Post-Retreatment Follow-Up
Week 20
 - ☐ Post-Retreatment Follow-Up
Week 24
 - ☐ Post-Retreatment Follow-Up
Week 28
 - ☐ Post-Retreatment Follow-Up
Month 7
 - ☐ Adverse Events
 - ☐ Concomitant Medication
 - ☐ Study Drug Administration
 - ☐ Study Drug Accountability
 - ☐ Pregnancy Report
 - ☐ Death
 - ☐ General Comments
-

Project Name: GS-US-248-0121
Form: General Comments [CO]
Generated On: 07-31-2013 09:44:51

☐ Unscheduled

☐ Study Completion

Project Name: GS-US-248-0121
Form: General Comments [CO]
Generated On: 07-31-2013 09:44:51

Form:

- ☐ Adverse Event
 - ☐ Adverse Event Summary
 - ☐ Complete Physical Examination
 - ☐ Concomitant Medication
 - ☐ Concomitant Medication Summary
 - ☐ Death Report
 - ☐ Demographics
 - ☐ Dose Administration (Day 1)
 - ☐ ECG
 - ☐ General Comments
 - ☐ Inclusion/Exclusion Criteria
 - ☐ Inclusion/Exclusion Criteria (Retreatment)
 - ☐ Investigator's Signature
 - ☐ Liver Fibrosis Assessment
 - ☐ Medical History
 - ☐ Pregnancy Report
 - ☐ Randomization
 - ☐ Stop Treatment
 - ☐ Study Completion
 - ☐ Study Drug Accountability - GS5885
 - ☐ Study Drug Accountability - GS5885 Retreatment
 - ☐ Study Drug Accountability - GS9451
 - ☐ Study Drug Accountability - GS9451 Retreatment
 - ☐ Study Drug Accountability - PEG
 - ☐ Study Drug Accountability - PEG Retreatment
 - ☐ Study Drug Accountability - RBV
 - ☐ Study Drug Accountability - RBV Retreatment
 - ☐ Study Drug Administration - Initial Treatment
 - ☐ Study Drug Administration - Retreatment
-

Project Name: GS-US-248-0121
Form: General Comments [CO]
Generated On: 07-31-2013 09:44:51

- ☐ Study Drug Completion (Initial Treatment)
 - ☐ Study Drug Completion (Retreatment)
 - ☐ Subject Follow-Up Status
 - ☐ Subject Number
 - ☐ Urine Pregnancy Test
 - ☐ Urine Pregnancy Test (Baseline)
 - ☐ Visit Date
 - ☐ Vital Signs
-

General Comments:

General Comments (Continued)

Note: To add additional comments, please complete an additional form, by clicking on 'Add a new log line'.

Project Name: GS-US-248-0121

Form: Inclusion/Exclusion Criteria (Retreatment) [IERTX]

Generated On: 07-31-2013 09:44:52

Did the subject meet all eligibility criteria?

☐ Yes

☐ No

If “No”, Please complete the following (Please tick all Inclusion criteria not met or Exclusion criteria met):

Inclusion/Exclusion criteria:

☐ Inclusion 1

☐ Exclusion 1

☐ Exclusion 2

Inclusion criteria not met/Exclusion criteria met?

☐

If subject that did not meet inclusion/exclusion criteria was enrolled, please provide an explanation.

Project Name: GS-US-248-0121
Form: Inclusion/Exclusion Criteria [IE]
Generated On: 07-31-2013 09:44:52

Date Informed Consent Signed: (DD-MMM-YYYY)

Under which protocol version was the subject enrolled?

☐ Amendment 1

☐ Amendment 2

Was subject a Screen Failure?

☐ Yes

☐ No

Did the subject meet all eligibility criteria?

☐ Yes

☐ No

If “No”, Please complete the following (Please tick all Inclusion criteria not met or Exclusion criteria met):

Inclusion/Exclusion criteria:

- ☐ Inclusion 1
 - ☐ Inclusion 2
 - ☐ Inclusion 3
 - ☐ Inclusion 4
 - ☐ Inclusion 5
 - ☐ Inclusion 6
 - ☐ Inclusion 7
 - ☐ Inclusion 8
 - ☐ Inclusion 9
 - ☐ Inclusion 10
 - ☐ Inclusion 11
 - ☐ Inclusion 12
 - ☐ Inclusion 13
 - ☐ Inclusion 14
 - ☐ Inclusion 15
 - ☐ Inclusion 16
 - ☐ Inclusion 17
 - ☐ Exclusion 1
 - ☐ Exclusion 2
 - ☐ Exclusion 3
 - ☐ Exclusion 4
 - ☐ Exclusion 5
 - ☐ Exclusion 6
 - ☐ Exclusion 7
 - ☐ Exclusion 8
 - ☐ Exclusion 9
 - ☐ Exclusion 10
 - ☐ Exclusion 11
 - ☐ Exclusion 12
-

Project Name: GS-US-248-0121
Form: Inclusion/Exclusion Criteria [IE]
Generated On: 07-31-2013 09:44:52

- ☐ Exclusion 13
- ☐ Exclusion 14
- ☐ Exclusion 15
- ☐ Exclusion 16
- ☐ Exclusion 17
- ☐ Exclusion 18
- ☐ Exclusion 19
- ☐ Exclusion 20
- ☐ Exclusion 21
- ☐ Exclusion 22
- ☐ Exclusion 23
- ☐ Exclusion 24
- ☐ Exclusion 25
- ☐ Exclusion 26
- ☐ Exclusion 27
- ☐ Exclusion 28
- ☐ Exclusion 29

Inclusion criteria not met/Exclusion criteria met?

☐

If subject that did not meet inclusion/exclusion criteria was enrolled, please provide an explanation.

For subjects who are screen failures but meet eligibility criteria - ONLY:
Provide the most significant reason why the subject was not randomized in the IWRS.

- ☐ Adverse Event
 - ☐ Investigator Decision
 - ☐ Subject Withdrew Consent
 - ☐ Lost to Follow-Up
 - ☐ Outside of Visit Window
 - ☐ Study Enrollment Closed
 - ☐ Other
-

Project Name: GS-US-248-0121

Form: Inclusion/Exclusion Criteria [IE]

Generated On: 07-31-2013 09:44:52

If "Other", specify:

Project Name: GS-US-248-0121

Form: Investigator's Signature *[INVSIG]*

Generated On: 07-31-2013 09:44:52

By entering my Medidata password, I affirm that I have reviewed and evaluated the case report forms and verify that they accurately reflect the information in the source documents for this subject. I understand source documentation can include (but is not limited to) medical records, laboratory results, x-rays, electronic communications, etc.

Project Name: GS-US-248-0121
Form: Liver Fibrosis Assessment [BIOPSY]
Generated On: 07-31-2013 09:44:52

LIVER BIOPSY

Check if Biopsy not done: ☐

Date of Liver Biopsy: (DD-MMM-YYYY)

Fibrosis Staging Method:

☐ Metavir

☐ Ishak

☐ Knodell

Fibrosis Staging Result:

☐ F0

☐ F0-F1

☐ F1

☐ F1-F2

☐ F2

☐ F2-F3

☐ F3

☐ F3-F4

☐ F4

☐ F5

☐ F6

Cirrhosis:

☐ Yes

☐ No

NON-INVASIVE ALTERNATIVE TO LIVER BIOPSY

Check if not done: ☐

Date of Procedure: (DD-MMM-YYYY)

Project Name: GS-US-248-0121
Form: Liver Fibrosis Assessment [BIOPSY]
Generated On: 07-31-2013 09:44:52

Method:	<div><input type="checkbox"/> FibroTest</div> <div><input type="checkbox"/> FibroScan</div> <div><input type="checkbox"/> Acoustic Radiation Force Impulse Imaging</div> <div><input type="checkbox"/> HepaScore</div> <div><input type="checkbox"/> Other</div>
If Method is Other, please specify:	<div></div>
Result:	<div></div>
Cirrhosis	<div><input type="checkbox"/> Yes</div> <div><input type="checkbox"/> No</div>

Project Name: GS-US-248-0121
Form: Medical History [MH]
Generated On: 07-31-2013 09:44:52

Please record date of diagnosis for Hepatitis C on row 1 and confirm as ongoing by checking the 'Ongoing' box.

In addition, click on the 'Add a new Log line' link below and add any relevant medical history.

Condition:	<input type="text"/>
------------	----------------------

Start Date: (DD-MMM-YYYY)	<input type="text" value="/ /"/>
---------------------------	----------------------------------

Stop Date: (DD-MMM-YYYY)	<input type="text" value="/ /"/>
--------------------------	----------------------------------

Check if Condition is Ongoing:	<input type="checkbox"/>
--------------------------------	--------------------------

Note: To add additional Medical History entries, please complete an additional form, by clicking on 'Add a new log line'.

Project Name: GS-US-248-0121
Form: Pregnancy Report [PREGREP]
Generated On: 07-31-2013 09:44:52

If a pregnancy occurs, please complete as much information as possible on this form.

In addition to this eCRF, refer to the regulatory binder and complete the 'Pregnancy Report' and email or fax the report within 24 hours of the reporter's knowledge of the event. When the outcome of the pregnancy is known, complete the 'Pregnancy Outcome Report'. (Click the [?] help text to open the Pregnancy Report Form in another window. Please fill in all information before faxing the forms to the appropriate CRO contact.)

Contact information for faxing and e-mailing these forms is found in the study protocol in section 8.5

Please also report the pregnancy to the Ribavirin Pregnancy Registry at ribavirinpregnancyregistry.com

Contact information for faxing and e-mailing these forms:

Australia/New Zealand (PRA Pharmacovigilance)

Fax +1 (888) 772-6919

Phone +1 (800) 772-2215

Email: CHO_safety@praintl.com

USA/Canada (DCRI Pharmacovigilance)

Fax +1 (866) 668-7139

Phone +1 (866) 668-7799

Email: safetysurveillance@mc.duke.edu

Last Menstrual Period: (DD-MMM-YYYY)

Pregnancy Confirmed: (DD-MMM-YYYY)

Estimated Date of Delivery: (DD-MMM-YYYY)

(Click the [?] help text to open the Pregnancy Outcome Report Form in another window. Please fill in all information on the first 3 pages before faxing the forms to the appropriate CRO contact.)

Project Name: GS-US-248-0121

Form: Randomization [RAND]

Generated On: 07-31-2013 09:44:52

Note: All baseline tests and procedures, including ECGs, must be completed prior to randomization and dosing/dispensing of study drugs.

Was the Subject Randomized?

☐ Yes
☐ No

4-Digit Subject Number as assigned by IWR system

Treatment Arm

☐ Arm 1 (GS-5885/GS-9451/RBV/PEG)
☐ Arm 2 (RBV/PEG)

Will the subject participate in Pharmacogenomic Testing?

☐ Yes
☐ No

Date of Pharmacogenomic Testing Consent: (DD-MMM-YYYY)

RANDNUM+Z_SUBID

Project Name: GS-US-248-0121

Form: Registry Substudy [REGISTRY]

Generated On: 07-31-2013 09:44:52

Which Registry study is the subject eligible to enroll in?

☐

None

☐

SVR Registry (248-0122)

☐

Sequence Registry (248-0123)

☐

NA, Site Not Participating

Will the subject enroll in the registry study?

☐

Yes

☐

No

If No, state the primary reason why the subject will not enroll?

☐

Subject is not interested in participating

☐

Subject will receive other HCV treatment

☐

Lost to follow-up

☐

Other

Other, specify

Project Name: GS-US-248-0121

Form: Retreatment Substudy Status *[RTS]*

Generated On: 07-31-2013 09:44:52

Will the subject enroll in the retreatment sub-study?

☐ Yes

☐ No

Did the subject have a confirmed viral relapse?

☐ Yes

☐ No

Did the subject have a viral breakthrough?

☐ Yes

☐ No

Will the subject need to complete the Screening Retreatment Visit?

☐ Yes

☐ No

Project Name: GS-US-248-0121

Form: Stop Treatment - Retreatment Substudy [SPTREAT2]

Generated On: 07-31-2013 09:44:52

Will the subject be stopping treatment after 24 weeks of retreatment?

☐ Yes

(Note: Subjects who meet eRVR criteria from Week 4 to Week 20 of the retreatment substudy should stop retreatment at Week 24)

☐ No

Project Name: GS-US-248-0121

Form: Stop Treatment [SPTREAT]

Generated On: 07-31-2013 09:44:52

Does the subject meet Early Responder criteria to continue current treatment?

☐ Yes

☐ No

Has the subject been instructed to stop treatment by the IWR system?

☐ Yes

☐ No

Project Name: GS-US-248-0121

Form: Study Completion [STUDCOMP]

Generated On: 07-31-2013 09:44:52

Did the subject complete the protocol-planned duration of the study?

☐ Yes

☐ No

If "No", please specify reason for study discontinuation.

☐ Adverse Event

☐ Death

☐ Pregnancy

☐ Efficacy Failure

☐ Protocol Violation

☐ Subject Withdrew Consent

☐ Lost to Follow-Up

☐ Investigator Decision

☐ Study Discontinued by Sponsor

Project Name: GS-US-248-0121

Form: Study Drug Accountability - GS-5885 Retreatment [DA1_RT]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline Retreatment
☐ Week 4 Retreatment
☐ Week 8 Retreatment
☐ Week 12 Retreatment
☐ Week 16 Retreatment
☐ Week 20 Retreatment
☐ Unscheduled

Drug Name:

- ☐ GS-5885
☐ GS-9451
☐ RBV
☐ PEG
☒ GS-5885 Retreatment
☐ GS-9451 Retreatment
☐ RBV Retreatment
☐ PEG Retreatment

Date Dispensed:

5-Digit Bottle Number:

Number of Tablets Dispensed:

Date Returned:

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - GS-5885 [DA1]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline
- ☐ Week 4
- ☐ Week 8
- ☐ Week 12
- ☐ Week 16
- ☐ Week 20
- ☐ Unscheduled

Drug Name:

- ☒ GS-5885
- ☐ GS-9451
- ☐ RBV
- ☐ PEG
- ☐ GS-5885 Retreatment
- ☐ GS-9451 Retreatment
- ☐ RBV Retreatment
- ☐ PEG Retreatment

Date Dispensed:

5-Digit Bottle Number:

Number of Tablets Dispensed:

Date Returned:

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - GS-9451 Retreatment [DA3_RT]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline Retreatment
- ☐ Week 4 Retreatment
- ☐ Week 8 Retreatment
- ☐ Week 12 Retreatment
- ☐ Week 16 Retreatment
- ☐ Week 20 Retreatment
- ☐ Unscheduled

Drug Name:

- ☐ GS-5885
- ☐ GS-9451
- ☐ RBV
- ☐ PEG
- ☐ GS-5885 Retreatment
- ☒ GS-9451 Retreatment
- ☐ RBV Retreatment
- ☐ PEG Retreatment

Date Dispensed:

5-Digit Bottle Number:

Number of Tablets Dispensed:

Date Returned:

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - GS-9451 [DA3]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline
☐ Week 4
☐ Week 8
☐ Week 12
☐ Week 16
☐ Week 20
☐ Unscheduled

Drug Name:

- ☐ GS-5885
☒ GS-9451
☐ RBV
☐ PEG
☐ GS-5885 Retreatment
☐ GS-9451 Retreatment
☐ RBV Retreatment
☐ PEG Retreatment

Date Dispensed:

5-Digit Bottle Number:

Number of Tablets Dispensed:

Date Returned:

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - PEG Retreatment [DA5_RT]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline Retreatment
- ☐ Week 4 Retreatment
- ☐ Week 8 Retreatment
- ☐ Week 12 Retreatment
- ☐ Week 16 Retreatment
- ☐ Week 20 Retreatment
- ☐ Week 24 Retreatment
- ☐ Week 28 Retreatment
- ☐ Week 32 Retreatment
- ☐ Week 36 Retreatment
- ☐ Week 40 Retreatment
- ☐ Week 44 Retreatment
- ☐ Unscheduled

Drug Name:

- ☐ GS-5885
- ☐ GS-9451
- ☐ RBV
- ☐ PEG
- ☐ GS-5885 Retreatment
- ☐ GS-9451 Retreatment
- ☐ RBV Retreatment
- ☒ PEG Retreatment

Date Dispensed:

Lot Number

Number of Syringes Dispensed:

Date Returned:

Project Name: GS-US-248-0121

Form: Study Drug Accountability - PEG Retreatment [DA5_RT]

Generated On: 07-31-2013 09:44:52

Number of Unused Syringes Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - PEG [DA5]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline
- ☐ Week 4
- ☐ Week 8
- ☐ Week 12
- ☐ Week 16
- ☐ Week 20
- ☐ Unscheduled

Drug Name:

- ☐ GS-5885
- ☐ GS-9451
- ☐ RBV
- ☒ PEG
- ☐ GS-5885 Retreatment
- ☐ GS-9451 Retreatment
- ☐ RBV Retreatment
- ☐ PEG Retreatment

Date Dispensed:

Lot Number

Number of Syringes Dispensed:

Date Returned:

Number of Unused Syringes Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - RBV Retreatment [DA4_RT]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline Retreatment
- ☐ Week 4 Retreatment
- ☐ Week 8 Retreatment
- ☐ Week 12 Retreatment
- ☐ Week 16 Retreatment
- ☐ Week 20 Retreatment
- ☐ Week 24 Retreatment
- ☐ Week 28 Retreatment
- ☐ Week 32 Retreatment
- ☐ Week 36 Retreatment
- ☐ Week 40 Retreatment
- ☐ Week 44 Retreatment
- ☐ Unscheduled

Drug Name:

- ☐ GS-5885
- ☐ GS-9451
- ☐ RBV
- ☐ PEG
- ☐ GS-5885 Retreatment
- ☐ GS-9451 Retreatment
- ☒ RBV Retreatment
- ☐ PEG Retreatment

Date Dispensed:

6-Digit Lot Number:

Number of Tablets Dispensed:

Date Returned:

Project Name: GS-US-248-0121

Form: Study Drug Accountability - RBV Retreatment [DA4_RT]

Generated On: 07-31-2013 09:44:52

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Accountability - RBV [DA4]

Generated On: 07-31-2013 09:44:52

Visit Dispensed:

- ☐ Baseline
☐ Week 4
☐ Week 8
☐ Week 12
☐ Week 16
☐ Week 20
☐ Unscheduled

Drug Name:

- ☐ GS-5885
☐ GS-9451
☒ RBV
☐ PEG
☐ GS-5885 Retreatment
☐ GS-9451 Retreatment
☐ RBV Retreatment
☐ PEG Retreatment

Date Dispensed:

6-Digit Lot Number:

Number of Tablets Dispensed:

Date Returned:

Number of Tablets Returned:

Study Drug Not Returned:

☐

Project Name: GS-US-248-0121

Form: Study Drug Administration - Initial Treatment [EX]

Generated On: 07-31-2013 09:44:52

Drug Name:

☐ GS-5885

☐ GS-9451

☐ RBV

☐ PEG

Dose:

Dose Units / Frequency:

☐ ug/week

☐ tablets/day

☐ Other

If "Other", please specify:

Start Date: (DD-MMM-YYYY)

Stop Date: (DD-MMM-YYYY)

Ongoing:

☐

Check box if study drug was permanently discontinued:

☐

Project Name: GS-US-248-0121

Form: Study Drug Administration - Retreatment [EX_RETREAT]

Generated On: 07-31-2013 09:44:52

Drug Name:

- ☐ GS-5885 Retreatment
- ☐ GS-9451 Retreatment
- ☐ RBV Retreatment
- ☐ PEG Retreatment

Dose:

Dose Units / Frequency:

- ☐ ug/week
- ☐ tablets/day
- ☐ Other

If "Other", please specify:

Start Date: (DD-MMM-YYYY)

Stop Date: (DD-MMM-YYYY)

Ongoing:

☐

Check box if study drug was permanently discontinued:

☐

Project Name: GS-US-248-0121

Form: Study Drug Completion (Initial Treatment) [SDRGCOMP]

Generated On: 07-31-2013 09:44:52

Did subject complete study drug treatment through the response guided duration of therapy?

☐ Yes

☐ No

If "No", please specify reason for study drug discontinuation:

☐ Adverse Event

☐ Death

☐ Pregnancy

☐ Efficacy Failure

☐ Protocol Violation

☐ Subject Withdrew Consent

☐ Lost to Follow-Up

☐ Investigator Decision

☐ Randomized but Subject Never
Dosed with Study Drug

☐ Study Discontinued by Sponsor

Project Name: GS-US-248-0121

Form: Study Drug Completion (Retreatment) [SDRGCOMP1]

Generated On: 07-31-2013 09:44:52

Did subject complete study drug re-treatment through the protocol-planned duration of the study?

☐ Yes

☐ No

If "No", please specify reason for study drug discontinuation

☐ Adverse Event

☐ Death

☐ Pregnancy

☐ Efficacy Failure

☐ Protocol Violation

☐ Subject Withdrew Consent

☐ Lost to Follow-Up

☐ Investigator Decision

☐ Study Discontinued by Sponsor

Project Name: GS-US-248-0121

Form: Subject Follow-Up Status *[DS]*

Generated On: 07-31-2013 09:44:53

Provide the subject status:

If subject has discontinued, please complete the Study Completion form. For female subjects of childbearing potential, please also continue to complete the follow-up Urine Pregnancy Tests until Month 7.

Project Name: GS-US-248-0121

Form: Subject Number *[SUBID]*

Generated On: 07-31-2013 09:44:53

Screening Number (XXX):

Subject Initials (XXX):

SCRNID + SUBJINIT

Project Name: GS-US-248-0121

Form: Urine Pregnancy Test (Baseline) [PREGTEST1]

Generated On: 07-31-2013 09:44:53

Is female subject of childbearing potential?

☐ Yes

☐ No

Date Test Performed: (DD-MMM-YYYY)

Test Result:

☐ Negative

☐ Positive

☐ Not Done

Note: A positive urine pregnancy test must be immediately confirmed with a serum pregnancy test, and the subject must not be enrolled.

Project Name: GS-US-248-0121
Form: Urine Pregnancy Test [PREGTEST]
Generated On: 07-31-2013 09:44:53

Is female subject of childbearing potential?

☐ Yes

☐ No

Date Test Performed: (DD-MMM-YYYY)

Test Result:

☐ Negative

☐ Positive

☐ Not Done

Note: A positive urine pregnancy test must be immediately confirmed with a serum pregnancy test.

Project Name: GS-US-248-0121

Form: Visit Date [VISDT]

Generated On: 07-31-2013 09:44:53

Was Post-Treatment Follow-Up Week 4 visit performed?

☐ Yes

☐ No

Was Post-Retreatment Follow-Up Week 4 visit performed?

☐ Yes

☐ No

Visit Date: (DD-MMM-YYYY)

Reason for Unscheduled Visit: (Check all that apply)

Evaluation of AE and/or Concomitant Medications:

☐

Vital Signs:

☐

Physical Exam:

☐

ECG:

☐

Lab Evaluations:

☐

Study Drug Adjustment or Dispensation:

☐

Other:

☐

Other, Specify:

Project Name: GS-US-248-0121

Form: Vital Signs [VS]

Generated On: 07-31-2013 09:44:53

Weight:

kg/ lb

Height:

cm/ in

Blood Pressure Systolic: (mmHg)

Blood Pressure Diastolic: (mmHg)

Pulse (beats/minute):

Respiration: (breaths/minute)

Temperature:

Celsius/
Fahrenheit
